Compound 21 for Preeclampsia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores why women who experienced preeclampsia during pregnancy might face higher risks of heart disease later. Researchers examine how the body's tiny blood vessels function in these women and whether activating certain receptors with Compound 21 (an Angiotensin II Type 2 Receptor Agonist) can restore normal function. The study focuses on women 12 weeks to 5 years post-pregnancy, comparing those who had preeclampsia to those who did not. Women who had preeclampsia but not other conditions like hypertension or diabetes before pregnancy might be suitable for this study. As an Early Phase 1 trial, this research aims to understand how the treatment works in people, offering participants a chance to contribute to groundbreaking insights.
Will I have to stop taking my current medications?
If you are currently taking antihypertensive or cholesterol-lowering medications, you cannot participate in this trial. The protocol does not specify about other medications, so it's best to discuss with the trial team.
Is there any evidence suggesting that Compound 21 is likely to be safe for humans?
Research has shown that Compound 21 has potential based on earlier studies. It activates the angiotensin type 2 receptor, which can protect blood vessels. In animal studies, this compound improved blood flow and reduced high blood pressure.
This trial remains in the early stages, so detailed safety information for humans is limited. However, some studies suggest that the compound is generally well-tolerated. These early results are promising, but more research is needed to fully understand its safety and effects in humans.12345Why do researchers think this study treatment might be promising for preeclampsia?
Unlike the standard treatments for preeclampsia, which typically focus on managing symptoms like high blood pressure with medications such as antihypertensives, Compound 21 works differently by targeting the microvasculature. Researchers are excited about this treatment because it involves delivering Compound 21 directly to the skin's tiny blood vessels using a technique called intradermal microdialysis. This approach not only offers a novel mechanism by potentially improving blood vessel function, but also allows for localized treatment, reducing the risk of systemic side effects. This innovative method could pave the way for more effective and safer management of preeclampsia.
What evidence suggests that Compound 21 might be an effective treatment for preeclampsia?
Research has shown that Compound 21, administered to participants in this trial, might address issues related to preeclampsia. Compound 21 improves blood flow and relaxes blood vessels by targeting specific areas that regulate blood pressure and inflammation. Dysfunction in these areas has been linked to preeclampsia. Additionally, Compound 21 may reduce inflammation, offering extra protection. This raises hope that Compound 21 could aid in managing long-term heart and blood vessel issues associated with preeclampsia.12367
Who Is on the Research Team?
Anna Reid-Stanhewicz, PhD
Principal Investigator
University of Iowa
Are You a Good Fit for This Trial?
This trial is for women aged 18-45 who experienced preeclampsia between 12 weeks and 5 years ago. It's also open to those who had healthy pregnancies. Participants should not be currently pregnant, planning pregnancy, have a history of hypertension or metabolic disease before pregnancy, use tobacco, or take certain medications like antihypertensives or statins.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo intradermal microdialysis for the local delivery of compound 21 and L-NAME to the cutaneous microvasculature
Follow-up
Participants are monitored for changes in microvascular blood flow response and angiotensin receptor expression
What Are the Treatments Tested in This Trial?
Interventions
- Compound 21
Find a Clinic Near You
Who Is Running the Clinical Trial?
Anna Stanhewicz, PhD
Lead Sponsor